Hanmi started to develop the first generic of Nexavar, a targeted anti-cancer drug
Hanmi Pharm has begun to develop the first generic of Nexavar(generic name: sorafenib), a liver cancer treatment.
According to the Ministry of Food and Drug Safety on the 16th, it has recently approved a plan to conduct bioequivalent tests of sorafenib, applied by Hanmi Pharm.
Nexavar, a multi-...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
